Drug Patents owned by Azurity

1. Drug name - EPANED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786482 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10154987 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US9669008 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10772868 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US11040023 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US11141405 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US11173141 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10039745 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US9808442 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Treatment: Treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; method of treatment of heart failure; treatment of heart failure; Method of treatment of heart failure; treatment of heart failure; method of treating hypertension; method of treating left ventricular dysfunction; treatment of hypertension

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
1MG/ML SOLUTION;ORAL Prescription

2. Drug name - FIRVANQ KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959949 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10959947 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10959948 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Treatment: Treatment of c. difficile-associated diarrhea; treatment of staphylococcal enterocolitis; Treatment of staphylococcal enterocolitis; treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE/ML FOR SOLUTION;ORAL Prescription
EQ 50MG BASE/ML FOR SOLUTION;ORAL Prescription

3. Drug name - KATERZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894039 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10959991 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10952998 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10695329 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10799453 AZURITY Amlodipine formulations Apr, 2039

(16 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Treatment: Treatment of hypertension; method of treating hypertension; Angina pectoris; angina

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML SUSPENSION;ORAL Prescription

4. Drug name - QBRELIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265370 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US9463183 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US11179434 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US10940177 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US9616096 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US9814751 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US10039800 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US10406199 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

Drugs and Companies using LISINOPRIL ingredient

Treatment: Treatment of hypertension; method of treating hypertension; treatment of heart failure; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; acute myocardial infarction; method of treatment of heart failure; Acute myocardial infarction; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; method of treatment of heart failure; treatment of heart failure; treatment of hypertension; method of treating hypertension; Treatment of myocardial infarction; method of treating hypertension; treatment of heart failure; method of treatment of heart failure; reduction of mortality in acute myocardial infarction; treatment of hypertension; acute myocardial infarction

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
1MG/ML SOLUTION;ORAL Prescription

5. Drug name - XATMEP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259427 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US10610485 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US10231927 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US11116724 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US9855215 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

Drugs and Companies using METHOTREXATE SODIUM ingredient

Treatment: A method for treating acute lymphoblastic leukemia; treatment of juvenile rheumatoid arthritis; Treatment of juvenile rheumatoid arthritis; a method for treating acute lymphoblastic leukemia

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE/ML SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.